Inventera Prices KOSDAQ IPO at Top of Range as Strong Demand Signals Confidence in Nano-MRI Pipeline

Seoul, March 19, 2026 — Inventera, a South Korean biotech firm specializing in next-generation nano-based MRI contrast agents, has set its initial public offering (IPO) price at the upper end of its target range, reflecting robust investor enthusiasm.

The company announced on Wednesday that it finalized the offering price at 16,600 won per share after a five-day book-building process for institutional investors. This represents the top of the previously indicated band of 12,100–16,600 won.

Inventera plans to offer 1.18 million shares in the listing, which is expected to raise approximately 19.6 billion won ($14.2 million). Demand was exceptionally strong, with a competition ratio of 1,328.82 to 1. Out of 2,309 participating institutions, 95.06% submitted bids at or above the top price.

Founded in 2018, Inventera develops advanced MRI contrast agents based on a biocompatible iron (Fe) nano-structure designed to offer higher safety and superior contrast performance compared to conventional agents. The company’s pipeline has drawn particular attention for its potential across multiple medical indications.

“Institutional investors showed great interest in the breadth of potential indications and the scalability of Inventera’s NANO-MRI contrast agent pipeline,” an official from lead manager NH Investment & Securities said.

CEO Shin Taehyun expressed confidence in the company’s technology and future growth as it prepares to go public.

Retail investor subscriptions will be accepted on March 23 and 24, with the company aiming to list on the KOSDAQ market in early April. NH Investment & Securities and Eugene Investment & Securities served as joint lead managers for the IPO.